Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation


ABSTRACT

Purpose
This guideline presents screening, assessment, and treatment approaches for the management of adult cancer survivors who are experiencing symptoms of fatigue after completion of primary treatment.

Methods
A systematic search of clinical practice guideline databases, guideline developer Web sites, and published health literature identified the pan-Canadian guideline on screening, assessment, and care of cancer-related fatigue in adults with cancer, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines In Oncology (NCCN Guidelines) for Cancer-Related Fatigue and the NCCN Guidelines for Survivorship. These three guidelines were appraised and selected for adaptation.

Results
It is recommended that all patients with cancer be evaluated for the presence of fatigue after completion of primary treatment and be offered specific information and strategies for fatigue management. For those who report moderate to severe fatigue, comprehensive assessment should be conducted, and medical and treatable contributing factors should be addressed. In terms of treatment strategies, evidence indicates that physical activity interventions, psychosocial interventions, and mind-body interventions may reduce cancer-related fatigue in post-treatment patients. There is limited evidence for use of psychostimulants in the management of fatigue in patients who are disease free after active treatment.

Conclusion
Fatigue is prevalent in cancer survivors and often causes significant disruption in functioning and quality of life. Regular screening, assessment, and education and appropriate treatment of fatigue are important in managing this distressing symptom. Given the multiple factors contributing to post-treatment fatigue, interventions should be tailored to each patient’s specific needs. In particular, a number of nonpharmacologic treatment approaches have demonstrated efficacy in cancer survivors.

J Clin Oncol 32. © 2014 by American Society of Clinical Oncology

INTRODUCTION

Recent advances in cancer screening and treatment have resulted in an expanding number of cancer survivors. The American Cancer Society estimates that as of January 2012, there were 13.7 million cancer survivors in the United States, and this number is estimated to rise to nearly 18 million by 2022.¹ The American Society of Clinical Oncology (ASCO) has taken steps to address the recommendations made by the Institute of Medicine (IOM)² to promote evidence-based, comprehensive, compassionate, and coordinated survivorship care.³ More specifically, the ASCO Cancer Survivorship Committee has mobilized to address recommendation three of the IOM, which calls for the “use of systematically developed evidence-based clinical practice guidelines, assessment tools, and screening instruments to help identify and manage late effects of cancer and its treatment. Existing guidelines should be refined and new evidence-based guidelines should be developed through public-and private-sector efforts.”¹² The guideline addresses one of a series of topics that have been identified and prioritized for development in cancer survivorship.

A majority of patients will experience some level of fatigue during their course of treatment; however, approximately 30% of patients will endure...
**GUIDELINE QUESTION**

What are the screening, assessment, and treatment approaches to the management of adult cancer survivors who are experiencing symptoms of fatigue after completion of primary treatment?

**Target Population**
- This practice guideline pertains to cancer survivors diagnosed at age ≥ 18 years who have completed primary cancer treatment with curative intent and are in clinical remission off therapy as well as patients who are disease free and have transitioned to maintenance or adjuvant therapy (eg, patients with breast cancer receiving hormonal therapy, patients with chronic myelogenous leukemia receiving tyrosine kinase inhibitors).

**Target Audience**
- This guidance is intended to inform health care professionals (eg, medical, surgical, and radiation oncologists, psychosocial and rehabilitation professionals, primary care providers, nurses, and others involved in the delivery of care for survivors) as well as patients, family members, and caregivers of patients who have survived cancer.

**Recommendations**

**Screening**
- All health care providers should routinely screen for the presence of fatigue from the point of diagnosis onward, including after completion of primary treatment.
- All patients should be screened for fatigue as clinically indicated and at least annually.
- Screening should be performed and documented using a quantitative or semiquantitative assessment.

**Comprehensive and Focused Assessment**

**History and Physical**
- Perform a focused fatigue history
- Evaluate disease status
- Assess treatable contributing factors.
- As a shared responsibility, the clinical team must decide when referral to an appropriately trained professional (eg, cardiologist, endocrinologist, mental health professional, internist, and so on) is needed.

**Laboratory Evaluation**
- Consider performing laboratory evaluation based on presence of other symptoms and onset and severity of fatigue.

**Treatment and Care Options**

**Education and Counseling**
- All patients should be offered specific education about fatigue after treatment (eg, information about the difference between normal and cancer-related fatigue, persistence of fatigue after treatment, and causes and contributing factors).
- Patients should be offered advice on general strategies that help manage fatigue.
- If treated for fatigue, patients should be observed and re-evaluated on a regular basis to determine whether treatment is effective or needs to be reassessed.

**Contributing Factors**
- Address all medical and treatable contributing factors first (eg, pain, depression, anxiety, emotional distress, sleep disturbance, nutritional deficit, activity level, anemia, medication adverse effects, and comorbidities).

**Physical Activity**
- Initiating/maintaining adequate levels of physical activity can reduce cancer-related fatigue in post-treatment survivors.

(continued on following page)
persistent fatigue for a number of years after treatment.\textsuperscript{6,7} Fatigue is one of the most prevalent and distressing long-term effects of cancer treatment, significantly affecting patients’ quality of life.\textsuperscript{6} The objective of this guideline is to identify evidence-based clinical practice guidelines, assessment tools, and screening instruments to help health care professionals care for survivors of adult-onset cancers who are experiencing symptoms of fatigue after completion of primary treatment.

ASCO has established a process for adapting other organizations’ clinical practice guidelines. This article summarizes the results of that process and presents the adapted practice recommendations.

The clinical question of focus is: What are the optimal screening, assessment, and treatment approaches in the management of adult cancer survivors who are experiencing symptoms of fatigue after completion of primary treatment? This practice guideline pertains to cancer survivors diagnosed at age \( \geq 18 \) years who have completed primary cancer treatment with curative intent and are in clinical remission off therapy as well as patients who are disease free and have transitioned to maintenance or prophylactic therapy (eg, patients with breast cancer receiving hormonal therapy, patients with chronic myelogenous leukemia receiving tyrosine kinase inhibitors). This guideline is intended to inform professional health care providers (eg, medical, surgical, and radiation oncologists, psychosocial and rehabilitation professionals, primary care providers, nurses, and others involved in the delivery of care for survivors) as well as patients, family members, and caregivers of patients who have survived cancer.

**METHODS**

This guideline adaptation was informed by the ADAPTE methodology,\textsuperscript{8} which was used as an alternative to de novo guideline development for this guideline. Adaptation of guidelines is considered by ASCO in selected circumstances, when one or more quality guidelines from other organizations already exist on the same topic. The objective of the ADAPTE process (http://www.adapte.org/) is to take advantage of existing guidelines to enhance efficient production, reduce duplication, and promote the local uptake of quality guideline recommendations.
The ASCO adaptation process begins with a literature search to identify candidate guidelines for adaptation. Adapted guideline manuscripts are reviewed and approved by the ASCO Clinical Practice Guidelines Committee (CPGC). The review includes two parts: methodologic review and content review. The methodologic review is completed by a member of the CPGC Methodology Subcommittee and/or by ASCO senior guideline staff. The content review is completed by an ad hoc panel (Appendix Table A1, online only), with guidance from an advisory group (Appendix Table A2, online only), convened by ASCO that includes multidisciplinary representation. Additional details on the methods used for the development of this guideline are reported in a Data Supplement.

Disclaimer

The information contained in this article, including but not limited to clinical practice guidelines and other guidance, is based on the best available evidence at the time of creation and is provided by ASCO to assist providers in clinical decision making. The information should not be relied on as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified herein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular product or course of medical treatment. Furthermore, the information is not intended to substitute for the independent professional judgment of the treating provider, because the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like must, must not, should, and should not indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in certain cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an as is basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

Guideline and Conflicts of Interest

The expert panel was assembled in accordance with the ASCO Conflicts of Interest Management Procedures for Clinical Practice Guidelines (summarized at http://www.asco.org/guidelinescoi). Members of the panel completed the ASCO disclosure form, which requires disclosure of financial and other interests that are relevant to the subject matter of the guideline, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as the result of promulgation of the guideline. Categories for disclosure include employment relationships, consulting arrangements, stock ownership, honoraria, research funding, and expert testimony. In accordance with these procedures, the majority of the members of the panel did not disclose any such relationships.

RESULTS

GUIDELINE SEARCH AND ASCO PANEL CONTENT REVIEW

As mentioned, the adaptation process starts with a literature search to identify candidate guidelines for adaptation on a given topic. The systematic search of clinical practice guideline databases, guideline developer Web sites, and published health literature was conducted to identify clinical practice guidelines, systematic reviews, meta-analyses, and other guidance documents addressing the screening, assessment, and care of cancer-related fatigue (see the Data Supplement on www.asco.org/guidelines for details of the search). On the basis of content review of the search yield, the ad hoc panel selected the pan-Canadian guideline on fatigue published in 2011,9 which is informed by recommendations from the Oncology Nursing Society10 and National Comprehensive Cancer Network (NCCN).11 The panel also considered two NCCN Guidelines12,13 that had been created or updated since 2009. These guidelines were selected because they were comprehensive and recently developed by multidisciplinary panels of experts.

Overview of Pan-Canadian and NCCN Guidelines

Clinical questions and target populations. The pan-Canadian guideline6 describes assessment after screening and effective interventions for management of fatigue in adults with cancer who are identified as experiencing symptoms of fatigue or tiredness using the Edmonton Symptom Assessment System (ESAS; further information on ESAS can be found in pan-Canadian guideline6). This practice guideline pertains to adults with cancer at any phase of the cancer continuum, regardless of cancer type, disease stage, or treatment modality. This practice guideline is intended to inform Canadian health authorities, program leaders, and administrators as well as health care professionals who provide care to adults with cancer. The guideline is interprofessional in focus, and the recommendations are applicable to direct-care providers (eg, nurses, social workers, family practitioners) in diverse care settings.

The NCCN Guideline for Cancer-Related Fatigue12 describes procedures for the assessment and management of fatigue in patients with cancer. The target population includes children, adolescents, and adults, and the guideline is intended to provide guidance for health care professionals as they implement it in their respective institutions and clinical practice. The NCCN Guideline for Survivorship13 consists of screening, evaluation, and treatment recommendations for common consequences of cancer and cancer treatment. The target population for this guideline is survivors who have completed treatment and are in clinical remission. It is intended for health care professionals who work with survivors of adult-onset cancer in the post-treatment period.

Summary of development methodology and key evidence of pan-Canadian and NCCN guidelines. The pan-Canadian guideline6 used systematic methods to search for evidence and clearly describes the strengths and limitations of the body of evidence and the methods used for formulating recommendations. The NCCN guideline12,13...
represent a consensus of experts; they are based on evidence, well respected, and widely used, and as such, they were included as supplementary evidence. All three guidelines offer comprehensive and user-friendly algorithms helpful in informing screening, assessment, and treatment options.

**ASCO METHODOLOGIC REVIEW**

From the identified guidelines and reviews, the pan-Canadian guideline on screening, assessment, and care of cancer-related fatigue in adults with cancer was singled out and underwent an expedited review by two content experts, who suggested that the guideline be accepted with modifications. After a second review, the ASCO panel suggested that the more recent NCCN Guideline for Cancer-Related Fatigue and NCCN Guideline for Survivorship also be included in the adaptation. A methodologic review of the three guidelines was completed by two ASCO staff members using the Rigour of Development subscale of the AGREE II (Appraisal of Guidelines for Research and Evaluation II) instrument (www.agreecollaboration.org). The Rigour of Development subscale consists of seven items that assess the quality of processes used to gather and synthesize relevant data and methods used to formulate guideline recommendations. The ASCO panel suggested that the guideline be modified from the pan-Canadian guideline, which received a score of 86.5%, the NCCN Guideline for Cancer-Related Fatigue received a score of 47%, and the NCCN Guideline for Survivorship received a score of 44%.

**ASCO UPDATED LITERATURE SEARCH**

Because the literature search included in the pan-Canadian guideline was only current to 2009, an additional search was undertaken. The MEDLINE and EMBASE databases were systematically searched by one reviewer from January 2009 to March 2013 using a combination of the following search terms: fatigue, cancer, survivor, post-treatment, late effects, and long-term effects. Reference lists of reviews were also extensively searched for studies on fatigue in the cancer survivor population. The located meta-analyses, systematic reviews, and randomized controlled trials were used as a supplementary evidence base for the recommendations and are cited where appropriate in the text.

**RECOMMENDATIONS**

**Screening**

*Modified from pan-Canadian guideline and NCCN Guideline for Cancer-Related Fatigue.*

- All health care providers should routinely screen for the presence of fatigue from the point of diagnosis onward, including after completion of primary treatment.
- All patients should be screened for fatigue as clinically indicated and at least annually.
- Screening should be performed and documented using a quantitative or semiquantitative assessment. For example, on a 0 to 10 numeric rating scale (0, no fatigue; 10, worst fatigue imaginable), mild fatigue is indicated as a score of 1 to 3, moderate fatigue as 4 to 6, and severe fatigue as 7 to 10.15,16 Because fatigue is rarely an isolated symptom, a multisymptom screening tool may have greater clinical utility. Patients who report moderate to severe fatigue should undergo a comprehensive and focused assessment.

Table 1 lists selected instruments for the measurement of fatigue, which could be used to supplement initial screening with the 0 to 10 numeric scale.

**Comprehensive and Focused Assessment**

*Modified from NCCN Guideline for Survivorship.* Regarding history and physical, first, perform a focused fatigue history, including:

- Onset, pattern, and duration.
- Change over time.
- Associated or alleviating factors.

Second, evaluate disease status by:

- Evaluating risk of recurrence based on stage, pathologic factors, and treatment history.
- Performing a review of systems to determine if other symptoms substantiate suspicion for recurrence.

Third, assess treatable contributing factors, including:

- Comorbidities (Table 2).
- Medications (consider persistent use of sleep aids, pain medications, or antiemetics).
- Alcohol/substance abuse.
- Nutritional issues (including weight/caloric intake changes).
- Decreased functional status.
- Deconditioning/decreased activity level.

As a shared responsibility, the clinical team must decide when referral to an appropriately trained professional (eg, cardiologist, endocrinologist, mental health professional, internist, and so on) is needed.

**Laboratory Evaluation**

*Modified from NCCN Guideline for Survivorship verbatim.*
• Consider performing laboratory evaluation based on presence of other symptoms, onset, and severity of fatigue.
• Complete blood cell count with differential; compare end-of-treatment hemoglobin/hematocrit with current values; assess other cell lines (WBC and platelets).
• Comprehensive metabolic panel: assess electrolytes; assess hepatic and renal function.
• Endocrinologic evaluation: TSH [thyroid-stimulating hormone]; consider more comprehensive evaluation or referral to specialist if other symptoms present.

Treatment and Care Options

Modified from pan-Canadian guideline and NCCN Guideline for Cancer-Related Fatigue. Regarding education and counseling:
• All patients should be offered specific education about fatigue after treatment (eg, information about the difference between normal and cancer-related fatigue, persistence of fatigue after treatment, and causes and contributing factors).
• Patients should be offered advice on general strategies that help manage fatigue (eg, physical activity, guidance on self-monitoring of fatigue levels).

A

Screening and Assessment – Fatigue in Cancer Survivors

Routinely screen for fatigue

Use a numeric rating scale as clinically indicated and at least annually.

Education and Counseling

• All patients should be offered specific education about fatigue following treatment (eg, information about the difference between normal and cancer-related fatigue, persistence of fatigue post treatment, and causes and contributing factors). All patients should be offered advice on general strategies that help manage fatigue (eg, maintaining physical activity) and guidance on self-monitoring of fatigue levels.

Comprehensive and Focused Assessment
(for patients who report moderate to severe fatigue)

History and Physical
1) Perform a focused fatigue history, including:
• Onset, pattern, duration
• Change over time
• Associated or alleviating factors
2) Evaluate disease status by:
• Evaluate risk of recurrence based on stage, pathologic factors, and treatment history
• Perform review of systems to determine if other symptoms substantiate suspicion for recurrence
3) Assess treatable contributing factors:
• Comorbidities (eg, cardiac dysfunction, endocrine dysfunction, pulmonary dysfunction, renal dysfunction, anemia, arthritis, neuromuscular complications, sleep disturbances, pain, emotional distress)
• Medications (consider persistent use of sleep aids, pain medications, or antiemetics)
• Alcohol/substance abuse
• Nutritional issues
  o Weight/caloric intake changes
  o Deconditioning

Laboratory Evaluation
• Consider performing laboratory evaluation based on presence of other symptoms, onset, and severity of fatigue
• CBC with differential
  o Compare end-of-treatment hemoglobin/hematocrit with current values
  o Assess other cell lines (WBC and platelets)
• Comprehensive metabolic panel
  o Assess electrolytes
  o Assess hepatic and renal function
• Endocrinologic evaluation
  o TSH
  o Consider more comprehensive evaluation or referral to specialist if other symptoms present

As a shared responsibility, the clinical team must decide when referral to an appropriately trained professional (eg, cardiologist, endocrinologist, mental health professional, internist) is needed.

Fig 1. Screening and assessment of fatigue in cancer survivors. CBC, complete blood cell count; TSH, thyroid-stimulating hormone. Data adapted with permission.®
If treated for fatigue, patients should be observed and re-evaluated on a regular basis to determine whether treatment is effective or needs to be reassessed.

**Treatment of Contributing Factors**
Modified from pan-Canadian guideline and NCCN Guideline for Survivorship. Address all medical and substance-induced treatable contributing factors first (e.g., pain, depression, anxiety, emotional distress, sleep disturbance, nutrition deficit, activity level, anemia, medication side-effects, and comorbidities). See Table 2 for more details.

**Interventions for Cancer-Related Fatigue**
Some patients may also benefit from interventions described below to treat fatigue. Currently, there are no clear standards for selecting among these for an individual patient. Further research is needed to establish a strategy for prioritizing, sequencing, and linking the available options. If treated for fatigue, patients should be followed and re-evaluated on a regular basis to determine whether treatment is effective or needs to be reassessed.

**Physical Activity**
- Initiating/maintaining adequate levels of physical activity can reduce cancer-related fatigue in post-treatment survivors.
- Actively encourage all patients to engage in a moderate level of physical activity after cancer treatment (e.g., 150 minutes of moderate aerobic exercise [such as fast walking, cycling, or swimming] per week with an additional 2 to 3 strength training [such as weight lifting] sessions per week, unless contraindicated.
- Walking programs are generally safe for most cancer survivors; the American College of Sports Medicine recommends that cancer survivors can begin this type of program after consulting with their doctors, but without any formal exercise testing (such as a stress test).
- Survivors at higher risk of injury (e.g., those living with neuropathy, cardiomyopathy, or other long-term effects of therapy other than comorbidities) should be referred to a physical therapist or exercise specialist. Breast cancer survivors with lymphedema should also consider meeting with an exercise specialist before initiating upper body strength-training exercise.

**Psychosocial Interventions**
- Cognitive behavioral therapy/behavioral therapy can reduce fatigue in cancer survivors.
- Psychoeducational therapies/educational therapies can reduce fatigue in cancer survivors.
- Survivors should be referred to psychosocial service providers who specialize in cancer and are trained to deliver empirically based interventions. Psychosocial resources that address fatigue may also be available through the National Cancer Institute (e.g., Moving Beyond Breast Cancer videos).

**Mind-Body Interventions**
- There is some evidence that the following interventions can reduce fatigue in cancer survivors:
  - Mindfulness-based approaches
  - Yoga
  - Acupuncture
- The following interventions may offer some benefit; however, additional research, particularly in the post-treatment population, is needed:
  - Biofield therapies (touch therapy), massage, music therapy, relaxation, reiki, qigong

**Pharmacologic Interventions**
- Evidence suggests that psychostimulants (e.g., methylphenidate) and other wakefulness agents (e.g., modafinil) can be effectively used to manage fatigue in patients with advanced disease or those on active treatment. However, there is very limited evidence of their effectiveness in reducing fatigue in patients who are disease free following active treatment, outside of the treatment of obstructive sleep apnea.
- Small pilot studies have evaluated the impact of supplements, such as ginseng and vitamin D, for cancer-related fatigue. However, there is no consistent evidence of their effectiveness.

**Ongoing Monitoring and Follow-up**
Promote ongoing self-monitoring of fatigue levels as a late or long-term cancer or treatment problem in post-treatment survivors.

---

**Fig 1.** Treatment and care map for fatigue in cancer survivors. Data adapted with permission. © 2014 by American Society of Clinical Oncology
trials have demonstrated that initiating or maintaining adequate levels of physical activity can reduce cancer-related fatigue in post-treatment patients. For example, a recent meta-analysis of 27 exercise intervention trials conducted with patients after treatment completion found that exercise training significantly reduced fatigue, with a mean effect size of 0.38 (95% CI, 0.21 to 0.43).27

Actively encourage all patients to engage in a moderate level of physical activity after cancer treatment (eg, 150 minutes of moderate aerobic exercise, such as fast walking, cycling, or swimming, per week with an additional two to three sessions per week of strength training, such as weight lifting, unless contraindicated).27-31

Walking programs are generally safe for most cancer survivors; the American College of Sports Medicine recommends that cancer survivors begin this type of program after consulting with their physician but without any formal exercise testing (such as a stress test).30

Survivors at higher risk of injury (eg, those living with neuropathy, cardiomyopathy, or other long-term effects of therapy...
other than comorbidities) should be referred to a physical therapist or exercise specialist. Breast cancer survivors with lymphedema should also consider meeting with an exercise specialist before initiating upper-body strength training.

Encourage survivors to make use of empirically based programs and local resources that are consistent with guideline recommendations. For patients with severe fatigue interfering with function, consider referral to a physical therapist or physiatrist.

Common barriers to physical activity in cancer survivors include physical and disease-related limitations (eg, illness, pain, fatigue, weakness) as well as lack of time, lack of interest/motivation, lack of facilities, and lack of encouragement from family or friends. To overcome these barriers, survivors should be encouraged to avoid inactivity by, at the minimum, engaging in exercises such as walking or using a stationary bicycle or cycle ergometer, beginning at an easy pace and progressing gradually to moderate intensity.

Survivors should be referred to practitioners specializing in physical therapy. For patients who are disease free after active treatment, outside of the treatment period, is needed:

- Biofield therapies (touch therapy), massage, music therapy, acupuncture, yoga, meditation, prayer, breath therapy, tai chi, and qi gong.
- Survivors should be referred to practitioners specializing in cancer and using protocols that have been empirically validated in cancer survivors.

**Psychosocial Interventions**

Modified from NCCN Guideline for Survivorship. Several meta-analyses, systematic reviews, and randomized trials have indicated that cognitive behavioral therapy/behavioral therapy can reduce fatigue in cancer survivors. For example, a cognitive behavioral intervention that targeted dysfunctional thoughts about fatigue, poor coping strategies, and dysregulated sleep and activity patterns in a mixed sample of fatigued cancer survivors led to significant improvements in fatigue and quality of life. Counseling and motivational interviewing have also been shown to encourage exercise adherence.

**Pharmacologic Interventions**

Modified from NCCN Guideline for Cancer-Related Fatigue and NCCN Guideline for Survivorship. Evidence suggests that psycho-stimulants (eg, methylphenidate) and other wakefulness agents (eg, modafinil) can be effectively used to manage fatigue in patients with advanced disease or those receiving active treatment. However, there is limited evidence of their effectiveness in reducing fatigue in patients who are disease free after active treatment, outside of the treatment of obstructive sleep apnea.

Small pilot studies have evaluated the impact of supplements, such as ginseng and vitamin D, for cancer-related fatigue. However, there is no consistent evidence of their effectiveness.

---

**Table 2. Potential Comorbid Conditions and Other Treatable Contributing Factors Possibly Associated With Fatigue Symptoms**

<table>
<thead>
<tr>
<th>Treatable Contributing Factor</th>
<th>Examples of Possible Diagnostic Evaluation*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac dysfunction (eg, arrhythmia, hypertension, coronary artery disease, congestive heart failure)</td>
<td>Consider echocardiogram, exercise test for cardiopulmonary reserve</td>
</tr>
<tr>
<td>Endocrine dysfunction (eg, diabetes, hypothyroidism, hypogonadism, adrenal insufficiency)</td>
<td>Consider measuring HgbA1C, TSH, glucose, and testosterone, conduct dexamethasone suppression test</td>
</tr>
<tr>
<td>Pulmonary dysfunction</td>
<td>Consider chest x-ray, 6-minute walk test, pulmonary function tests, oxygen saturation</td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>Consider kidney and electrolyte chemistries</td>
</tr>
<tr>
<td>Anemia</td>
<td>Consider CBC</td>
</tr>
<tr>
<td>Arthritis</td>
<td>Consider sedimentation rate, serologies</td>
</tr>
<tr>
<td>Neuromuscular complications (neuromuscular, neuopathy)</td>
<td>Consider grip strength test, neuropathy sensory testing, electromyography</td>
</tr>
<tr>
<td>Sleep disturbances (eg, insomnia, sleep apnea, vasomotor symptoms, restless leg syndrome)</td>
<td>Consider assessing sleep with standardized questionnaire, possible sleep study</td>
</tr>
<tr>
<td>Pain</td>
<td>Evaluate with standardized assessment tool</td>
</tr>
<tr>
<td>Emotional distress (eg, anxiety, depression)</td>
<td>Evaluate with standardized assessment tool or diagnostic interview</td>
</tr>
</tbody>
</table>

NOTE. This list is not meant to be exhaustive. Data adapted. Abbreviations: CBC, complete blood cell count; HgbA1C, hemoglobin A1C; TSH, thyroid-stimulating hormone.

*Should be undertaken only when clinically appropriate.
Ongoing Monitoring and Follow-Up

Promote ongoing self-monitoring of fatigue levels, using a symptoms diary or other methods, because fatigue can be a late or long-term problem in post-treatment survivors. ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate.

SPECIAL COMMENTARY

Although there are a number of guidelines and systematic reviews offering recommendations on the management of cancer-related fatigue, there is still relatively little guidance available for the management of fatigue in cancer survivors. The purpose of this guideline is to tailor the available information to this distinct population, because follow-up care for cancer survivors is often challenging, especially if they are dealing with comorbidities and receiving care from multiple providers. Patient follow-up and ongoing care should be individualized based on type of cancer, treatments received, overall health, and personal preferences. In many cases, the patient will be transitioned post-treatment to his or her primary care provider or a survivorship clinic. This transition may be eased with the use of survivorship care plans, which contain personalized information about the patient’s treatment and follow-up plans (examples provided in ASCO templates at http://www.cancer.net/survivorship/asco-cancer-treatment-summaries). It is estimated that by 2022, the number of cancer survivors in the United States will exceed 18 million. Therefore, there is a need for greater coordination of care among oncologists and primary care providers, development of evidence-based resources, and ongoing research focusing on the survivor population as well as education, training, and clinical tools that will improve overall patient experience and well-being. The cornerstone of progress for the patient with cancer is the rapport established with his or her health care team. Open and engaging communication will assist both the patient and health care providers in assessing the patient’s experience of fatigue and in determining an appropriate management strategy. ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate.

REFERENCES


ADDITIONAL RESOURCES

Additional information, including data supplements, evidence tables, and clinical tools and resources, can be found at www.asco.org/guidelines/. Patient information is available there and at www.cancer.net. The complete adapted guideline can be accessed at http://www.capo.ca/Fatigue_Guideline.pdf and http://www.nccn.org.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author’s immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None Consultant or Advisory Role: None Stock Ownership: None Honoraria: None Research Funding: Carmelita P. Escalante, Pfizer; Patricia A. Ganz, Amgen; Gary Lyman, Amgen; Paul Jacobsen, Pfizer Expert Testimony: None Patents, Royalties, and Licenses: None Other Remuneration: None

Manuscript writing: All authors

Final approval of manuscript: All authors

AUTHOR CONTRIBUTIONS

Bower et al
Fatigue in Adult Cancer Survivors

Acknowledgment

We thank Bryan Rumble for assisting with the methodologic guideline review; Tom Oliver and Mark Somerfield for administrative assistance; and the Survivorship Guideline Advisory Group, Clinical Practice Guidelines Committee (CPGC), and CPGC reviewers Jennifer Mack, MD, and Julia Rowland, PhD, for their thoughtful reviews and insightful comments on this guideline.

Appendix

Table A1. Members of Fatigue Panel

<table>
<thead>
<tr>
<th>Panel Member</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julienne E. Bower, PhD (cochair), psychology</td>
<td>Departments of Psychology and Psychiatry/Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA</td>
</tr>
<tr>
<td>Paul B. Jacobsen, PhD (cochair), psychology</td>
<td>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL</td>
</tr>
<tr>
<td>Ann Berger MSN, MD, pain and palliative care</td>
<td>National Institutes of Health Clinical Center, Bethesda, MD</td>
</tr>
<tr>
<td>William Breitbart, MD, psychiatry</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>Carmelita P. Escalante, MD, internal medicine</td>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>Patricia A. Ganz, MD, medical oncology</td>
<td>Schools of Medicine and Public Health, University of California at Los Angeles, Los Angeles, CA</td>
</tr>
<tr>
<td>Hester Hill Schnipper, LICSW, BCD, patient representative, oncology social work</td>
<td>Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
<tr>
<td>Jennifer A. Ligibel, MD, medical oncology</td>
<td>Dana-Farber Cancer Institute, Boston, MA</td>
</tr>
<tr>
<td>Gary H. Lyman, MD, MPH, FASCO, FRCP, medical oncology</td>
<td>Duke University and Duke Cancer Institute, Durham, NC</td>
</tr>
<tr>
<td>Mohammed S. Ogaily, MD, FACP, ASCO PGIN representative, medical oncology</td>
<td>Oakwood Center for Hematology and Oncology–Downriver, Brownstown, MI</td>
</tr>
<tr>
<td>William F. Pirl, MD, psychiatry</td>
<td>Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>Kate Bak, MSc</td>
<td>ASCO, Alexandria, VA</td>
</tr>
<tr>
<td>Christina Lacchetti, MHSc</td>
<td>ASCO, Alexandria, VA</td>
</tr>
</tbody>
</table>

Abbreviations: ASCO, American Society of Clinical Oncology; PGIN, Practice Guidelines Implementation Network.

Table A2. Members of Survivorship Guideline Advisory Group

<table>
<thead>
<tr>
<th>Member</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Lyman (cochair)</td>
<td>Duke University and Duke Cancer Institute, Durham, NC</td>
</tr>
<tr>
<td>Smita Bhatia (cochair)</td>
<td>City of Hope Comprehensive Cancer Center, Duarte, CA</td>
</tr>
<tr>
<td>Louis S. Constine</td>
<td>University of Rochester Medical Center, Rochester, NY</td>
</tr>
<tr>
<td>Melissa M. Hudson</td>
<td>St Jude Children’s Research Hospital, Memphis, TN</td>
</tr>
<tr>
<td>Julia Howe Rowland</td>
<td>National Institutes of Health, Bethesda, MD/Department of Health and Human Services, Washington, DC</td>
</tr>
<tr>
<td>Kevin C. Oeffinger</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>Donna E. Maziarz</td>
<td>The Ottawa Hospital, General Campus, Ottawa, ON</td>
</tr>
<tr>
<td>Larisa Neklyudov</td>
<td>Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>Wendy Landier</td>
<td>City of Hope, Duarte, CA</td>
</tr>
<tr>
<td>Paul B. Jacobsen</td>
<td>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL</td>
</tr>
<tr>
<td>Mark Gorman</td>
<td>Patient Representative, Silver Spring, MD</td>
</tr>
<tr>
<td>Anthony Magdalinski</td>
<td>ASCO PGIN; Abington Health Lansdale Hospital, Lansdale, PA; Doylestown Hospital, Doylestown, PA; Grand View Hospital, Sellersville, PA; St Luke’s Quakertown Hospital, Quakertown, PA</td>
</tr>
</tbody>
</table>

Abbreviations: ASCO, American Society of Clinical Oncology; PGIN, Practice Guidelines Implementation Network.